Plain-English translation of NCT06977711 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether — a targeted antibody therapy — combined with and standard chemotherapy can improve outcomes for people with newly diagnosed, high-risk diffuse large B-cell lymphoma. You would receive two initial rounds of the new medications paired with a well-known antibody called , followed by six rounds of standard chemotherapy (called R-CHOP) combined with the same medications. The trial aims to see if this combination is safe and effective.
Diffuse large B-cell lymphoma is an aggressive cancer, and even with current standard treatment, many patients experience relapse or don't respond well. Researchers believe that adding and to the standard approach might improve how many patients achieve long-term remission.
You likely qualify if…
You likely don't qualify if…
You would attend clinic visits every 3 weeks for a total of 8 cycles (about 6 months of active treatment). In the first two cycles, you would receive intravenous infusions of the new medications plus , along with an oral daily pill. Then for six more cycles, you would continue with intravenous chemotherapy (R-CHOP) plus the same medications. Throughout the trial, you would have imaging scans (PET-CT) at four time points and blood tests to monitor how well the treatment is working and to check your health and safety.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States